Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: salirasib | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 8,529 | 0.82 |
| pathways Reactome | 68 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 12105
Sealed predictions
- NRAS in dopamine neurons, braak-0.10 (p 0.799) → +0.79 (p 0.011)receipt 12113
Swarm cases
receipt 12113: NRAS in dopamine neurons, braak
- power
- full sample +0.15 (p 0.555, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.05 (p 0.854, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.08 (p 0.748, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.30, sign flips 0; without severely affected donors +0.15 (p 0.555, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NRAS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts